PDS Biotechnology Corporation (NASDAQ:PDSB) is set to announce third quarter earning results on Wednesday 11th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, PDSB to report 3Q20 loss of $ 0.2 per share.
For the full year, analysts anticipate loss of $ 0.83 per share bottom line.
Stock Performance
Shares of PDS Biotechnology Corporation traded up $ 0.07 or 3.43 percent on Tuesday, reaching $ 2.11 with volume of 479.70 thousand shares. PDS Biotechnology Corporation has traded high as $ 2.23 and has cracked $ 1.94 on the downward trend
The closing price of $ 2.11, representing a 229.03 % increase from the 52 week low of $ 0.62 and a 59.04 % decrease over the 52 week high of $ 4.98.
The company has a market capital of $ 46.97 million and is part of the Healthcare sector and Biotechnology industry.
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. It develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company lead product candidate is PDS0101, an immunotherapeutic for the treatment of cancer.
